DeepMatter Group PLC Collaboration (1347N)
28 Septiembre 2021 - 01:00AM
UK Regulatory
TIDMDMTR
RNS Number : 1347N
DeepMatter Group PLC
28 September 2021
28 September 2021
DeepMatter Group Plc
DeepMatter collaborates with Dr. Reddy's for its
DigitalGlassware(R) platform
DeepMatter Group Plc (AIM: DMTR, "DeepMatter", the "Group"), the
international digital chemistry data company, has signed a contract
with Dr. Reddy's Laboratories Limited ("Dr. Reddy's"), based in
Hyderabad, India, for its DigitalGlassware(R) platform.
DeepMatter will provide its DigitalGlassware(R) platform to Dr
Reddy's process development team who are looking to the development
and scale up of chemistry procedures to handover to colleagues.
This collaboration is part of DeepMatter's ongoing strategy to
provide its DigitalGlassware(R) platform to the major global
Contract Research Organisations (CRO's) where the need for
reproducibility is paramount to accelerate the discovery of new
drugs.
Dr. Reddy's manufactures and markets a wide range of
pharmaceuticals in India and overseas and has built strong R&D
capabilities not just in India, but worldwide, making it a partner
of choice in c ontract research, development, and manufacturing
services. As it seeks to constantly build on its digital
capabilities, DigitalGlassware(R) will look to play a key role in
this strategy.
DigitalGlassware(R) comprises a cloud-based software platform
allowing scientists to easily bring together digitised synthesis
protocols (recipes) and contextualised time-course sensor streams
from a range of analytical instrumentation, importantly in
real-time.
Mark Warne, CEO of DeepMatter Group, commented:
"We are focused on creating value for the world's largest CROs
with our DigitalGlassware(R) platform. We are working with them to
firmly establish it as the go-to platform for capturing and
structuring time-course sensor data in the lab, to enable improved
insights for better productivity and discovery.
" Dr Reddy's are actively interested in the capture of
parameters that they can utilise for their process development and
modelling activities. We are working with them to see how
DigitalGlassware(R), with the use of sensor devices, can aid in the
capture of these important parameters and facilitate analysis of
runs performed at Dr Reddy's . "
For more information, please contact:
DeepMatter Group Plc
Mark Warne, Chief Executive Officer 0141 548 8156
Canaccord Genuity Limited (Nominated Advisor and Broker) 020
7523 8000
Bobbie Hilliam
Meare Consulting
07990 858548
Adrian Duffield
About DeepMatter Group Plc
DeepMatter is building a unique, fully integrated digital
chemistry cloud platform of chemical reaction data for scientists,
who are working on early-stage chemical discovery &
development.
DeepMatter is integrating technology with chemistry to enable
scientists, principally in the commercial sector, to easily perform
and optimise chemistry. It is building, structuring and analysing
chemical reaction databases and using this substantial data for
real-time innovation and productivity gains in the chemical
industry - particularly pharmaceutical companies engaged in
pre-clinical drug discovery & development. This data is also
now enabling Artificial Intelligence (AI) driven chemical
automation.
Visit: www.deepmatter.io and follow @deepmattergroup
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for
healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products - Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy's operates in
markets across the globe. Our major markets include - USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTSEIFWWEFSELU
(END) Dow Jones Newswires
September 28, 2021 02:00 ET (06:00 GMT)
Deepmatter (LSE:DMTR)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Deepmatter (LSE:DMTR)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024